DEINOVE Announces Its Financial Calendar for 2019

MONTPELLIER, France--()--Regulatory News:

DEINOVE (Paris:ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-based active ingredients for cosmetics and nutrition, announces today its provisional financial calendar for 2019*.

March 28, 2019   Publication of 2018 Annual Results
May 20, 2019   Annual Shareholders Meeting, in Paris (2:00pm CET)

At Fieldfisher Law firm, 48, rue Cambon, 75001 Paris

September 26, 2019   Publication of 2019 First Half Financial Results

* This financial calendar is for indicative purposes only and the Company could change its publication dates should it deem necessary.

ABOUT DEINOVE

DEINOVE is a French biotechnology company, a leader in disruptive innovation, which aims to help meet the challenges of antibiotic resistance and the transition to a sustainable production model for the cosmetics and nutrition industries.

DEINOVE has developed a unique and comprehensive expertise in the field of rare bacteria that it can decipher, culture, and optimize to disclose unsuspected possibilities and induce them to produce biobased molecules with activities of interest on an industrial scale. To do so, DEINOVE has been building and documenting since its creation an unparalleled biodiversity bank that it exploits thanks to a unique technological platform in Europe.

DEINOVE is organized around two areas of expertise:

  • ANTIBIOTICS, New-generation anti-infectives: DEINOVE is preparing to enter a first antibiotic candidate into Phase II. The Company is also pursuing the systematic exploration of biodiversity to supply its portfolio with new leads, drawing notably on partnerships with Naicons and bioMérieux (AGIR program supported by Bpifrance).
  • BIOACTIVES, Active ingredients of natural origin with cosmetics as the first market and potential in nutrition and health: DEINOVE already markets a first innovative active ingredient, a second in partnership with Greentech, while two others are in development with Oléos (Hallstar Group). It also runs a program in animal nutrition with Groupe Avril. Several other partnerships are also being planned.

Within the Euromedecine science park located in Montpellier, DEINOVE employs 62 employees, mainly researchers, engineers, and technicians, and has filed more than 260 patent applications internationally. The Company has been listed on EURONEXT GROWTH® since April 2010.

Visit www.deinove.com

Contacts

Investors
Coralie Martin
Communication, Marketing and Investor Relations
Ph.: +33 (0)4 48 19 01 60
coralie.martin@deinove.com

Media
ALIZE RP
Aurore Gangloff / Catherine Mégélas
Ph.: +33 (0)1 44 54 36 66
deinove@alizerp.com

Contacts

Investors
Coralie Martin
Communication, Marketing and Investor Relations
Ph.: +33 (0)4 48 19 01 60
coralie.martin@deinove.com

Media
ALIZE RP
Aurore Gangloff / Catherine Mégélas
Ph.: +33 (0)1 44 54 36 66
deinove@alizerp.com